737 related articles for article (PubMed ID: 28770968)
1. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway.
Jin Y; Feng SJ; Qiu S; Shao N; Zheng JH
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3176-3184. PubMed ID: 28770968
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
3. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
4. MALAT1 affects ovarian cancer cell behavior and patient survival.
Lin Q; Guan W; Ren W; Zhang L; Zhang J; Xu G
Oncol Rep; 2018 Jun; 39(6):2644-2652. PubMed ID: 29693187
[TBL] [Abstract][Full Text] [Related]
5. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway.
Dong Y; Liang G; Yuan B; Yang C; Gao R; Zhou X
Tumour Biol; 2015 Mar; 36(3):1477-86. PubMed ID: 25431257
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer.
Qiu JJ; Lin YY; Ye LC; Ding JX; Feng WW; Jin HY; Zhang Y; Li Q; Hua KQ
Gynecol Oncol; 2014 Jul; 134(1):121-8. PubMed ID: 24662839
[TBL] [Abstract][Full Text] [Related]
7. LncRNA MALAT1 Facilitates Ovarian Cancer Progression through Promoting Chemoresistance and Invasiveness in the Tumor Microenvironment.
Mao TL; Fan MH; Dlamini N; Liu CL
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638541
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA MALAT1 promotes cholangiocarcinoma cell proliferation and invasion by activating PI3K/Akt pathway.
Wang C; Mao ZP; Wang L; Wu GH; Zhang FH; Wang DY; Shi JL
Neoplasma; 2017; 64(5):725-731. PubMed ID: 28592124
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer.
Xu S; Sui S; Zhang J; Bai N; Shi Q; Zhang G; Gao S; You Z; Zhan C; Liu F; Pang D
Int J Clin Exp Pathol; 2015; 8(5):4881-91. PubMed ID: 26191181
[TBL] [Abstract][Full Text] [Related]
10. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
Tang Y; Xiao G; Chen Y; Deng Y
Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer.
Cao Y; Shi H; Ren F; Jia Y; Zhang R
Exp Cell Res; 2017 Oct; 359(1):185-194. PubMed ID: 28754469
[TBL] [Abstract][Full Text] [Related]
12. LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/β-catenin signaling pathway.
Zhang Y; Dun Y; Zhou S; Huang XH
Biomed Pharmacother; 2017 Dec; 96():1216-1221. PubMed ID: 29239819
[TBL] [Abstract][Full Text] [Related]
13. LncRNA MALAT1 affects high glucose-induced endothelial cell proliferation, apoptosis, migration and angiogenesis by regulating the PI3K/Akt signaling pathway.
Zhang SH; Zhang SG; Zhou P; Wei X; Mao XD; Lin SG; Liu C
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8551-8559. PubMed ID: 31646587
[TBL] [Abstract][Full Text] [Related]
14. LncRNA LINC01305 silencing inhibits cell epithelial-mesenchymal transition in cervical cancer by inhibiting TNXB-mediated PI3K/Akt signalling pathway.
Yan SP; Chu DX; Qiu HF; Xie Y; Wang CF; Zhang JY; Li WC; Guo RX
J Cell Mol Med; 2019 Apr; 23(4):2656-2666. PubMed ID: 30697971
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MALAT1 expression inhibition suppresses tongue squamous cell carcinoma proliferation, migration and invasion by inactivating PI3K/Akt pathway and downregulating MMP-9 expression.
Yuan J; Xu XJ; Lin Y; Chen QY; Sun WJ; Tang L; Liang QX
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):198-206. PubMed ID: 30657561
[TBL] [Abstract][Full Text] [Related]
16. Capn4 Enhances Osteopontin Expression through Activation of the Wnt/β-Catenin Pathway to Promote Epithelial Ovarian Carcinoma Metastasis.
Yang X; Sun J; Xia D; Can X; Liu L; Zhang J; Xu H; Du N; Liu W; Shen F; Zhang Z; Sun Y; Xi X
Cell Physiol Biochem; 2017; 42(1):185-197. PubMed ID: 28535511
[TBL] [Abstract][Full Text] [Related]
17. The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma.
Chen S; Wu DD; Sang XB; Wang LL; Zong ZH; Sun KX; Liu BL; Zhao Y
Cell Death Dis; 2017 Oct; 8(10):e3118. PubMed ID: 29022892
[TBL] [Abstract][Full Text] [Related]
18. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway.
Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L
Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014
[TBL] [Abstract][Full Text] [Related]
19. Long non‑coding RNA MALAT1 correlates with cell viability and mobility by targeting miR‑22‑3p in renal cell carcinoma via the PI3K/Akt pathway.
Li Z; Ma Z; Xu X
Oncol Rep; 2019 Feb; 41(2):1113-1121. PubMed ID: 30431104
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA CPS1-IT1 is a positive prognostic factor and inhibits epithelial ovarian cancer tumorigenesis.
Wang YS; Ma LN; Sun JX; Liu N; Wang H
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3169-3175. PubMed ID: 28770969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
